Research programme: PARP-1 inhibitor prodrug - Radikal Therapeutics
Latest Information Update: 22 Jul 2016
At a glance
- Originator Radikal Therapeutics
- Class Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adult respiratory distress syndrome; Lung cancer